AVITA MEDICAL LTD SPON ADS EACH REP 20 ORD SHS RCEL 深 滬
等待開盤 10-24 09:30:00 美东时间
4.02
+0.060
+1.52%
華盛通- 最 高4.1387
- 今 開4.00
- 成交量 11.51万股
- 最 低 4.00
- 昨 收 3.96
- 總市值 1.07亿
- 52周最高 14.16
- 市盈率 靜 --
- 換手率 0.43%
- 52周最低 3.60
- 委 比 -50.00%
- 總股本 2661.89万
- 歷史最高 49.11
- 量 比 0.21
- 振 幅 3.50%
- 歷史最低 3.60
- 每 手 1
- 風險率 2.81%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在最高涨幅37.45%，甲骨文获多家机构上调目标价；瑞穗上调美光科技目标价升至240美元
今日重点评级关注：韦德布什：维持Artiva Biotherapeutics"跑赢大市"评级，目标价从18美元升至23美元；巴克莱：维持Cellectis"超配"评级，目标价从4美元升至8美元
10-20 10:03
AVITA Medical任命临时首席执行官
专注于皮肤修复设备及自体细胞疗法的开发和商业化企业AVITA Medical（RCEL）股价暴跌27.2%。该公司在董事会决定后，已任命Cary Vanc...
10-17 23:42
Reported Earlier, AVITA Medical Announces Leadership Transition With Cary Vance As Interim CEO And Preliminary Q3 Revenue Of $17M
Board Chairman Cary Vance appointed Interim CEOBoard member Jan Stern Reed appointed Lead Independent DirectorThird quarter 2025 preliminary revenue expected to be approximately $17 million
10-17 14:02
AVITA Medical Announces CEO Transition
AVITA Medical announces Cary Vance as Interim CEO and Jan Stern Reed as Lead Independent Director following Jim Corbett's departure. The company expects Q3 2025 revenue of ~$17 million and is seeking a permanent CEO, with Vance considered as a candidate.
10-16 22:15
AVITA Medical's RECELL Eligible For Up To $4,875 In CMS Reimbursement For Acute Trauma And Surgical Wounds
Hospitals may receive up to $4,875 in added reimbursement when using RECELL to treat non-burn full-thickness acute wounds resulting from trauma or surgeryEffective October 1, the add-on payment eases financial barriers,
10-01 20:35
CMS New Technology Add-On Payment Expands Access to RECELL® for Patients with Non-Burn Acute Wounds
As of October 1, 2025, U.S. hospitals using the RECELL System to treat acute, non-burn trauma and surgical full-thickness wounds are eligible for additional reimbursement of up to $4,875 per case under the Centers for Medicare & Medicaid Services (CMS) New Technology Add-on Payment program. The policy, effective through September 30, 2026, aims to reduce financial barriers and encourage broader use of the innovative skin cell therapy, which requi...
10-01 12:30
美股牛股 | 贝利石油大涨21%，与CRC达成合并协议；稀土概念股AREC涨超20%
C4 Therapeutics涨超34%，大行升其目标价至6美元；贝利石油大涨21%，与CRC达成合并协议；稀土概念股AREC涨超20%>>
09-16 15:15
再生医学公司Avita Medical公司（RCEL）股价飙升35%
美股周一早盘，再生医学公司Avita Medical公司（RCEL）股价飙升35%，此前其RECELL GO设备获得CE认证，推动股价上涨10%。该设备有助...
09-15 22:58
皮肤修复设备开发商Avita Medical(RCEL.US)RECELL GO系统获欧盟CE认证 盘前应声上涨
皮肤修复设备开发商Avita Medical的新一代自体细胞采集设备RECELL GO系统已获得欧盟医疗器械法规(EU MDR)下CE认证。
09-15 18:39
AVITA Medical Receives CE Mark For RECELL GO, Allowing The Co To Commercialize In Europe And In Other Markets That Recognize The CE Mark
AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))) ("AVITA Medical", or the "Company"), a leading therapeutic acute wound care company, today announced it has received the CE Mark under the European Union Medical Device
09-15 07:40
